Clinical trials: Signs and Symptoms, Digestive
Chronic Hepatitis B Virus, Pediatric
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection
- Trial name
- NCT01079806
- Testing
- Entecavir
- Where
- 44 sites in United States, Argentina and 12 more
- Volunteers
- 180 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
This open-label, multi-center study will evaluate the effect on the quantitative HBsAg reduction of peginterferon alfa-2a [PEGASYS] in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01086085
- Testing
- Adefovir, peginterferon alfa-2a [PEGASYS]
- Where
- 11 sites in China
- Volunteers
- 265 people
- Sponsor
- Hoffmann-La Roche
Constipation, Irregular Bowel Movement Frequency
IQP-PO-101 for the Regulation of Bowel Movement Frequency
The purpose of the study is to evaluate the safety and efficacy of IQP-PO-101 in regulating the bowel movement frequency
- Trial name
- NCT01809587
- Testing
- IQP-PO-101
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Short Bowel Syndrome, Short Gut Syndrome
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
MP-101 will be evaluated in this study to see if it is safe and tolerable.
- Conditions
- Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut
- Trial name
- NCT02246816
- Testing
- 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
- Where
- 5 sites in United States
- Sponsor
- Marathon Pharmaceuticals, LLC
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone.
- Trial name
- NCT02517021
- Testing
- Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 405 people
- Sponsor
- Helsinn Healthcare SA
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
Pancreatic Cancer, Ductal Adrenocarcinoma
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients…
- Conditions
- Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
- Trial name
- NCT01020006
- Testing
- PCI-27483, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pharmacyclics LLC.
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00040027
- Testing
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Bariatric Surgery Candidate, Cholelithiases
Safety and Feasibility of the Use of the Dual Robotic Arm Accessory With the Levita Magnetic Surgical System in Laparoscopic Procedures
The purpose of this study is to evaluate the safety and feasibility of the Levita Dual Robotic Arm Accessory (DRAA) used with the Levita Magnetic Surgical System (MSS)
- Conditions
- Bariatric Surgery Candidate, Cholelithiases, Other Disease
- Trial name
- MARS GI (NCT05695989)
- Testing
- Dual Robotic Arm Accessory (DRAA)
- Where
- 3 sites in Chile
- Volunteers
- 22 people
- Sponsor
- Levita Magnetics
Heartburn, Upper Abdominal Pain
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2…
- Conditions
- Heartburn, Upper Abdominal Pain, Nausea, Acid Regurgitation
- Trial name
- NCT00625274
- Testing
- Esomeprazole, Lansoprazole, Pantoprazole
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Hypoalbuminemia, Hepatic Cirrhosis
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA.
- Trial name
- NCT06355479
- Testing
- OsrHSA, Plasbumin®-20
- Where
- 37 sites in China
- Volunteers
- 328 people
- Sponsor
- Healthgen Biotechnology Corp.
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
Chronic Hepatitis C Infection
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as…
- Trial name
- PEARL-II (NCT01674725)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 187 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT00780910
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 109 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.
- Trial name
- ECLIPSE 1 (NCT01025596)
- Testing
- Interleukin-7
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Cytheris SA
Chronic Hepatitis B
Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients
The purpose is to evaluate efficacy and safety of therapeutic hepatitis B virus (HBV) vaccine (mimogen-based)) Joint entecavir treatment in chronic hepatitis B patients.
- Trial name
- NCT01326546
- Testing
- Therapeutic HBV vaccine, entecavir
- Where
- 15 sites in China
- Volunteers
- 378 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Short Bowel Syndrome (SBS)
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials.
- Trial name
- EASE SBS 6 (NCT07228403)
- Testing
- Glepaglutide 10 mg
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 28 people
- Sponsor
- Zealand Pharma
Hepatitis B, Chronic
Lamivudine(LAM) Good Responder Study
This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.
- Trial name
- LAMGR (NCT01128686)
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- ViiV Healthcare
Hepatitis C, Chronic
PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)
This study aims to evaluate the efficacy and safety of peginterferon alfa-2b plus weight-based ribavirin as initial treatment in chronic hepatitis C virus (HCV) genotype 1 patients.
- Trial name
- NCT00724620
- Testing
- Peginterferon alfa-2b (SCH 054031), Ribavirin (SCH 018908)
- Volunteers
- 103 people
- Sponsor
- Schering-Plough
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.